- Screening
- Preoperative indications
- Intraoperative indications
- Follow-up one week after aspiration
- Adverse events
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
- Design, Methods
Age ≥ 18 years old | Yes
|
Thyroid US indicates thyroid nodule. | Yes
|
US assessment accords with FNA criteria recommended by C-TIRADS | Yes
/No
|
nodule with high insufficient rate | suspected degenerative nodule
|
Informed consent | Yes
|
Allergic to lidocaine or SonoVue | No
|
Refuse to CEUS | No
|
Severe abnormality of heart function or lung function | No
|
Severe abnormality of coagulation function | No
|
Pregnancy | No
|
Active infectious focus on cervical skin | No
|
Patients unable to cooperate for FNA or CEUS | No
|
Registration number | 0000034016 |
Birthday | 1986-03-03 |
Sex | Female
|
Telephone | 13822142931 |
Date for signing informed consent | 2023-06-19 |
Location of target thyroid nodule | right lobe
|
transverse diameter | 5 mm |
Anteroposterior diameter | 7 mm |
Upper and lower diameter | 8 mm |
Solid component (%) | 100 |
echo | hypoecho
|
edge | clear
|
border | regular
|
acoustic halo | No
|
Strong echo within nodule | Sheet-like
|
Solid component of sheet-like strong echo (%) | 95 |
Score of ACR TI-RADS | 8 |
Rank of ACR TI-RADS | 5 |
Score of C-TIRADS | 2 |
Rank of C-TIRADS | 4b |
Ultrasonic diagnose | 退变结节与肿瘤鉴别 |
VCs function evaluated by TLUSG | bilateral VCs moved symmetrically
|
Routine blood test | Yes
|
Coagulation function | Yes
|
- Time of aspiration
- Contrast-enhance indication (CEUS-FNA group)
- Progression of operation
- Intraoperative instant complication
Date of aspiration | 2023-06-20 |
Start time | 15:59 |
End time | 16:06 |
Dosage of SonoVue | - |
No enhancement | No
|
Ratio of enhancement | - |
Injection of SonoVue during FNA | No
|
Machine | GE logiq E9
|
Local anesthesia | 2% lidocaine
|
other local anaesthesics | - |
Dosage of local anaesthesics | 4 ml |
Patient compliance | good
|
Aspiration needle | Italy 23G
|
FNA approach | lateral approach
|
Aspiration times | 4 |
Use of negative pressure | Yes
|
Pressure | 0.2 ml |
Quality of nodule | solid
|
Grittiness | Yes
|
Sample capacity | a little
|
Allergic to contrast agent | No
|
Painful | Yes
|
VAS score | 2 |
Analgesic | No
|
Painful when leave interventional room | No
|
Haemorrhage | No
|
Voice change | No
|
Vagal nerve syndrome | No
|
Horner syndrome | No
|
Aspiration related acute hypersensitivity reaction | No
|
location | |
visible for bleeding by CDFI | |
extend of hematoma (once after FNA) |
|
methods | |
visible hemorrhage by CDFI 30 minutes after FNA | |
extend of hematoma (before patient departure) | |
appearance | |
vocal cord mobility assessment by ultrasound | |
methods | |
whether the voice recovers when the patient leaves |
Pathological number |
|
Whether sample capacity is enough | |
Number of observable follicular epithelial cell clusters in specimen | |
Cytopathology classification |